Mads Krogsgaard Thomsen emphasized that Denmark's economy is not at risk of experiencing a Nokia-like downturn due to Novo Nordisk's influence, citing significant differences in their market dependencies.
Novo Nordisk has emerged as Europe's largest pharmaceutical company, with a market valuation of $373 billion, showcasing its importance to Denmark's economic landscape.
The Novo Nordisk Foundation, benefiting from the company's success, has established itself as a prominent philanthropic entity, surpassing even the Gates Foundation in asset management.
Analysts caution against the 'Nokia risk', pointing out that while Novo Nordisk bolsters Denmark's economy now, overreliance could pose future threats, similar to Finland's experience with Nokia.
Collection
[
|
...
]